Stem cell transplant with T cell depletion for inherited bone marrow failure
Tests a T cell depleted stem cell transplant in people with inherited bone marrow failure.
Key facts
- Who runs it
- Masonic Cancer Center, University of Minnesota
- Where
- Minneapolis, United StatesSee the site
- Trial code
- Registry title
- Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 48 people, planned
- Started
- 13 Nov 2018
- Expected to end
- 5 Jan 2029
- Type of study
- Interventional, 5 groups
- Treatments tested
- Total Body Irradiation (TBI) (Plan 1)
- Cyclophosphamide (CY) (Plan 1)
- Fludarabine (FLU)
- Methylprednisolone (MP)
- Donor mobilized PBSC infusion
- G-CSF
- Cyclophosphamide (CY) (Plan 2)
- Rituximab
- Busulfan
- Alemtuzumab
- Melphalan
- Record updated
- 30 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with an inherited bone marrow failure disorder (Fanconi anemia or a telomere biology disorder) who have certain risk factors and need a stem cell transplant.
- Age
- Under 65 years for Fanconi anemia; under 70 years for telomere biology disorders.
- Sex
- Men and women can join.
- Disease stage
- Fanconi anemia or a telomere biology disorder, with at least one risk factor such as severe aplastic anemia or myelodysplastic features. Fanconi anemia patients can also join with a high risk genotype or immune weakness with repeated infections.
Main reasons for not taking part
- Pregnant or breastfeeding
- Active, uncontrolled infection within 1 week before starting treatment
- Malignant solid tumor cancer within the previous 2 years
- Poor lung, heart or liver function
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- For FA patients:
- Diagnosis of Fanconi anemia; Age <65 years of age
- Has one of the following risk factors:; Severe aplastic anemia (SAA); Myelodysplastic features; High risk genotype; Immunodeficiency associated with history of recurrent infections
- Karnofsky performance status ≥ 70% if ≥ 16 years of age or Lansky play score ≥ 50% for patients <16 years of age; Adequate pulmonary, cardiac and liver function; Voluntary written consent (minor assent if appropriate) prior to the performance of any study related procedures not part of standard medical care; For TBD patients:
- Diagnosis of TBD
- Age <70 years of age
- Has one of the following risk factors:
- Severe aplastic anemia (SAA)
- Myelodysplastic features
- Karnofsky performance status ≥ 70% if ≥ 16 years of age or Lansky play score; ≥ 50% for patients <16 years of age
- Adequate pulmonary, cardiac and liver function
- Voluntary written consent (minor assent if appropriate) prior to the performance of any study related procedures not part of standard medical care
Who cannot take part
- Active, uncontrolled infection within 1 week prior to starting study therapy
- Malignant solid tumor cancer within previous 2 years; Donor Selection (Inclusion Criteria): meets one of the following match criteria:
- Voluntary written consent (parent/guardian and minor assent, if < 18 years) prior to the performance of any research related procedure
- Performance of a donor infectious disease screen panel including CMV Antibody, Hepatitis B Surface Antigen, Hepatitis B Core Antibody, Hepatitis C Antibody, HIV 1/2 Antibody, HTLVA 1/2 Antibody, Treponema, and Trypanosoma Cruzi (T. Cruzi) plus HBV, HCV, WNV, HIV by nucleic acid testing (NAT); and screening for evidence of and risks factors for infection with Zika virus, or per current standard institutional donor screen - must be negative for HIV and active hepatitis B
- Pregnant or breastfeeding as the treatment used in this study are Pregnancy Category D. Females of childbearing potential must have a negative pregnancy test (serum or urine) within 14 days of study registration
- Adequate organ function defined as:; Hematologic: hemoglobin, WBC, platelet within 10% of upper and lower limit of normal range of test (gender based for hemoglobin); Hepatic: ALT < 2 x upper limit of normal; Renal: serum creatinine < 1.8 mg/dl
- Body weight of at least 40 kilograms and at least 12 years of age
- an HLA-A, B, DRB1 matched sibling donor (matched sibling)
- an HLA-A, B, DRB1 matched related donor (other than sibling)
- a related donor mismatched at 1 HLA-A, B, C and DRB1 antigen
- 7-8/8 HLA-A,B,C,DRB1 allele matched unrelated donor per current institutional guidelines Patients and donors are typed for HLA-A and B using serological or molecular techniques and for DRB1 using high resolution molecular typing. If a donor has been selected on the basis of HLA-A, B, C and DRB1 typing as above, preference will be made for donors matched at the HLA-C locus
- Willing and able to undergo mobilized peripheral blood apheresis
- In general good health as determined by the medical provider
- Not pregnant - females of childbearing potential must have a negative pregnancy test within 7 days of mobilization start
Other criteria
- Patient Selection:
Where in United States
- Masonic Cancer Center at University of MinnesotaMinneapolis, United StatesContact: Lisa Burke, RNTaking people
About the trial
What the trial wants to find out
This is a phase II trial of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation in patients with inherited bone marrow failure (BMF) disorders to eliminate the need for routine graft-versus-host disease (GVHD) immune suppression leading to earlier immune recovery and potentially a reduction in the risk of severe infections after transplantation.
The 5 groups in the trial
- Treatment Plan 1: TBI 300 , CY, FLU, MP, Rituximab in patients with Fanconi AnemiaTreatment being tested
Given to: * Patients with an unrelated donor or HLA mismatched related donor, regardless of disease type OR * Patients with an HLA- identical sibling donor recipient and myelodysplastic features, MDS, or acute leukemia
Treatment: Total Body Irradiation (TBI) (Plan 1), Cyclophosphamide (CY) (Plan 1), Fludarabine (FLU), Methylprednisolone (MP), Donor mobilized PBSC infusion, G-CSF, and Rituximab
- Treatment Plan 2: CY, FLU, MP, Rituximab in patients with Fanconi AnemiaTreatment being tested
Given to: • An HLA-identical sibling donor recipients with single or multi- lineage hematopoietic failure
Treatment: Fludarabine (FLU), Methylprednisolone (MP), Donor mobilized PBSC infusion, G-CSF, Cyclophosphamide (CY) (Plan 2), and Rituximab
- Treatment Plan 3: BU, Cy, FLU, MP and Rituximab in patients with Fanconi AnemiaTreatment being tested
Given to: * Patients with an unrelated donor or HLA mismatched related donor, regardless of disease type who cannot tolerate TBI * Patients with an HLA- identical sibling donor recipient and myelodysplastic features, MDS, or acute leukemia who cannot tolerate TBI * Biallelic mutations in FANCD1/BRCA2 who cannot receive TBI * Per treating physician preference
Treatment: Cyclophosphamide (CY) (Plan 1), Fludarabine (FLU), Methylprednisolone (MP), Rituximab, and Busulfan
- Treatment Plan 4: CY, FLU, and alemtuzumabTreatment being tested
given to TBD patients with: * Bone marrow failure AND * Any donor type including haploidentical (4/8) to 8/8-HLA matched related donor, or 7-8/8 HLA-matched unrelated donor Based on historical numbers, it is expected approximately 3 patients would be treated per year. Statistical outcomes will be descriptive.
Treatment: Cyclophosphamide (CY) (Plan 1), Fludarabine (FLU), and Alemtuzumab
- Treatment Plan 5: CY, FLU, melphalan (MEL), and alemtuzumab.Treatment being tested
given to TBD patients with: * Early myelodysplastic features (with or without cytogenetic abnormalities) AND * Any donor type including haploidentical (4/8) to 8/8-HLA matched related donor, or 7-8/8 HLA-matched unrelated donor Based on historical numbers, it is expected approximately 2 patients would be treated per year. Statistical outcomes will be descriptive.
Treatment: Cyclophosphamide (CY) (Plan 1), Fludarabine (FLU), Alemtuzumab, and Melphalan
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- MT2017-17:T Cell Receptor Alpha/Beta T Cell Depleted Hematopoietic Cell Transplantation in Patients With Inherited Bone Marrow Failure (BMF) Disorders
- Plain-language title
- Stem cell transplant with T cell depletion for inherited bone marrow failureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 30 January 2026